Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030059520 A1
Publication typeApplication
Application numberUS 09/966,590
Publication dateMar 27, 2003
Filing dateSep 27, 2001
Priority dateSep 27, 2001
Also published asUS7763308, US20050098097, WO2003026716A1
Publication number09966590, 966590, US 2003/0059520 A1, US 2003/059520 A1, US 20030059520 A1, US 20030059520A1, US 2003059520 A1, US 2003059520A1, US-A1-20030059520, US-A1-2003059520, US2003/0059520A1, US2003/059520A1, US20030059520 A1, US20030059520A1, US2003059520 A1, US2003059520A1
InventorsYung-Ming Chen, Charles Bobson, John LoPrete
Original AssigneeYung-Ming Chen, Bobson Charles R., Loprete John F.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Apparatus for regulating temperature of a composition and a method of coating implantable devices
US 20030059520 A1
Abstract
An applicator for applying a coating substance to an implantable medical device, such as a stent, is provided. The applicator comprises a nozzle and a temperature controller in communication with the nozzle for adjusting the temperature of the coating substance. A method of using the applicator is also provided.
Images(2)
Previous page
Next page
Claims(16)
What is claimed is:
1. An applicator for applying a coating substance to an implantable medical device, comprising a nozzle and a temperature controller in thermal communication with the nozzle for adjusting the temperature of the coating substance during the application process.
2. The applicator of claim 1, wherein the temperature controller circumscribes the nozzle and is position in close proximity to an orifice of the nozzle through which the coating substance is applied.
3. The applicator of claim 1, wherein the coating substance includes a polymer dissolved in a solvent and optionally a therapeutic substance added thereto.
4. The applicator of claim 1, wherein the implantable device is a radially expandable stent.
5. An apparatus for applying a composition to a stent, comprising:
(a) an applicator for spraying a composition at the stent; and
(b) a temperature controller connected to the applicator for adjusting the temperature of the composition to a temperature other than ambient temperature.
6. The apparatus of claim 5, wherein the applicator comprises a body extending into a nozzle, such that the temperature controller is positioned in close proximity to the nozzle.
7. The apparatus of claim 5, wherein the applicator is an air-assisted internal or external mixing atomizer.
8. The apparatus of claim 5, additionally including a temperature modular in communication with the temperature controller for maintaining the temperature of the composition at a constant level during the application of the composition.
9. A method of coating a stent, comprising:
(a) positioning a stent at a distance away from a nozzle;
(b) applying a coating substance from the nozzle to the stent; and
(c) adjusting the temperature of the nozzle to adjust the temperature of the coating substance.
10. The method of claim 9, wherein a temperature controller is in thermal commutation with the nozzle for adjusting the temperature of the nozzle.
11. The method of claim 9, wherein the coating substance comprises a polymer dissolved in a solvent and optionally a therapeutic substance added thereto.
12. The method of claim 9, wherein the temperature of the nozzle is adjusted to a temperature of about 35° C. to about 40° C.
13. The method of claim 9, wherein the temperature of the nozzle is adjusted to a temperature above room temperature.
14. The method of claim 9, additionally including rotating the stent about the longitudinal axis of the stent.
15. The method of claim 9, wherein the coating substance is applied as atomized droplets.
16. The method of claim 9, wherein the temperature of the nozzle is adjusted prior to the application of the coating substance.
Description
    BACKGROUND OF THE INVENTION
  • [0001]
    1. Field of the Invention
  • [0002]
    This invention relates to an apparatus for applying a composition to an implantable device such as a stent and method for using the same to form a coating.
  • [0003]
    2. Description of the Background
  • [0004]
    Stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically stents are capable of being compressed, so that they can be inserted through small lumens via catheters, and then expanded to a larger diameter once they are at the desired location. Mechanical intervention via stents has reduced the rate of restenosis; restenosis, however, is still a significant clinical problem. Accordingly, stents have been modified to perform not only as a mechanical scaffolding, but also to provide biological therapy.
  • [0005]
    Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results.
  • [0006]
    A common method of medicating a stent is by depositing a polymeric coating, impregnated with the therapeutic substance, on the surface of the stent. A polymer dissolved in a solvent is applied to the stent. A therapeutic substance can be dissolved or dispersed in the composition. The solvent is allowed to evaporate to form the coating. The application of the composition can be performed by spraying the composition on the stent or immersing the stent in the composition.
  • [0007]
    Problems associated with the coating stents with a polymeric coating include formation of polymer “cob webs” between the stent struts, excessive gathering of clumps or “pool webs” of coating on the surface of the stent struts, and lack of uniformity of the coating. What is needed is, accordingly, an apparatus and process for coating stents that minimizes or significantly reduces the aforementioned defects.
  • SUMMARY OF THE INVENTION
  • [0008]
    In accordance with one aspect of the invention, an applicator for applying a coating substance to an implantable medical device, such as a stent, is provided. The applicator comprises a nozzle and a temperature controller in thermal communication with the nozzle for adjusting the temperature of the coating substance during the application process. In one embodiment, the temperature controller circumscribes the nozzle and is position in close proximity to an orifice of the nozzle through which the coating substance is applied. The coating substance can be a polymer dissolved in a solvent and optionally a therapeutic substance added thereto.
  • [0009]
    In accordance with another aspect of the invention, an apparatus for applying a composition to a stent is provided comprising an applicator for spraying a composition at the stent, and a temperature controller connected to the applicator for adjusting the temperature of the composition to a temperature other than room temperature. The applicator can include a body extending into a nozzle, such that the temperature controller is positioned in close proximity to the nozzle. The applicator can be an air-assisted internal or external mixing atomizer. The apparatus can additionally include a temperature modular in communication with the temperature controller for maintaining the temperature of the composition at a constant level during the application of the composition.
  • [0010]
    In accordance with anther aspect of the invention, a method of coating a stent is provided comprising positioning a stent at a distance away form a nozzle, applying a coating substance from the nozzle to the stent, and adjusting the temperature of the nozzle to adjust the temperature of the composition. The temperature of the nozzle can be adjusted to a temperature above room temperature, e.g., 35° C. to about 40° C.
  • BRIEF DESCRIPTION OF THE FIGURE
  • [0011]
    [0011]FIG. 1 illustrate an apparatus used to coat a stent in accordance with one embodiment of the invention.
  • DETAILED DESCRIPTION OF THE EMBODIMENTS Dispenser Assembly
  • [0012]
    Referring to FIG. 1, there is illustrated a dispenser assembly 10 for applying a composition to a medical device. Dispenser assembly 10 includes a source or solution barrel 12 for containing and supplying a coating composition to an applicator 14. Applicator 14 can include a body 16 and a nozzle 18 extending from body 16. Nozzle 18 includes an orifice 20 of any suitable size for allowing a composition to be sprayed from the applicator 14. Applicators are commercially available from Spray Systems Co., EFD International Inc., and Badger Air-Brush Co., one specific model of which is the EFD 780S spray device with VALVEMATE 7040 control system (East Providence, R.I.). Other types of spray applicators, including air-assisted internal mixing atomizers and ultrasonic applicators can also be used for the application of the composition. A temperature controller 22 can be used for adjusting the temperature of the composition to a temperature other than room temperature. In the illustrated embodiment, temperature controller 22 circumscribes nozzle 18 portion of applicator 14 and is positioned in close proximity to orifice 20. In one implementation of the device, such placement of temperature controller 22 allows for the heating of nozzle 22 at a concentrated area so as to prevent prolong exposure of the drug solution to the heat, which for heat sensitive drugs, such as actinomycine D, could prevent the degradation of the drug. The illustrated configuration allows the temperature of the composition to be adjusted contemporaneously with the spraying of the composition from nozzle 18. Heating of the solution will reduce surface tension and the viscosity of the solution, which are believed to be two key factors for achieving better coating uniformity and significantly minimizing the formation of “cob webs” between the stent struts and “pool webs” on the surface of the stent struts. Temperature controllers or thermal blocks are commercially available. One commercial example is EUROTHERM (model 2416). A control modulator 23 can be provided for monitoring and controlling the temperature of controller 22 and, if desired, maintaining the temperature of the composition at a constant rate during the application of the composition. As one option, the temperature of the composition can be adjusted at barrel 12.
  • Implantable Devices
  • [0013]
    [0013]FIG. 1 additionally illustrates a stent 24 mounted on a mandrel 26. Mandrel 26 can be coupled to a motor assembly 28 for providing rotational motion and/or transitional motion along railing 30 to stent 24. Stent is broadly intended to include self-expandable stents, balloon-expandable stents, and stent-grafts. One of ordinary skill in the art, however, understands that the apparatus and method of the invention can be used to coat other medical devices, such as grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, axius coronary shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be virtually any design. Stents are typically defined by tubular body having a network of bands or cylindrical elements interconnected by, for example, connecting elements. The particular structure of the stent is not of critical significance. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used.
  • The Composition
  • [0014]
    The embodiments of the composition can be prepared by conventional methods wherein all components are combined, then blended. More particularly, in accordance to one embodiment, a predetermined amount of a polymer or combination of polymers can be added to a predetermined amount of a solvent or a combination of solvents. If necessary, heating, stirring and/or mixing can be employed to effect dissolution of the polymer(s) into the solvent(s)—for example in an 80° C. water bath for two hours. A therapeutic substance can be also added to the composition. The therapeutic substance should be in true solution or saturated in the blended composition. If the therapeutic substance is not completely soluble in the composition, operations including mixing, stirring, and/or agitation can be employed to effect homogeneity of the residues. The therapeutic substance may be added so that dispersion is in fine particles. The mixing of the therapeutic substance can be conducted at ambient pressure and at room temperature.
  • [0015]
    The polymer or combination of polymers chosen must be biocompatible and minimize irritation to the vessel wall when the device is implanted. The polymer may be either a biostable or a bioabsorbable polymer. Bioabsorbable polymers that could be used include poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid. Also, biostable polymers with a relatively low chronic tissue response such as polyurethanes, silicones, and polyesters could be used. Other polymers include polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose. Ethylene vinyl alcohol is functionally a very suitable choice of polymer. The copolymer possesses good adhesive qualities to the surface of a stent, particularly stainless steel surfaces, and has illustrated the ability to expand with a stent without any significant detachment of the copolymer from the surface of the stent. The copolymer, moreover, allows for good control capabilities over the release rate of the therapeutic substance.
  • [0016]
    Representative examples of solvents include dimethylsulfoxide (DMSO), iso-propylalcohol (EPA), n-propylalcohol, tetrahydrofuran (THF), dimethylformamide (DMF), dimethyl acetamide (DMAC) or any other suitable solvent that is capable of placing the selected polymer into dissolution at the selected concentration and should not adversely react with the therapeutic substance.
  • [0017]
    The active agent could be for inhibiting the activity of vascular smooth muscle cells. More specifically, the active agent can be aimed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells for the inhibition of restenosis. The active agent can also include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. For example, the agent can be for enhancing wound healing in a vascular site or improving the structural and elastic properties of the vascular site. Examples of agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The active agent can also fall under the genus of antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOLŽ by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. TaxotereŽ, from Aventis S. A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. AdriamycinŽ from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. MutamycinŽ from Bristol-Myers Squibb Co., Stamford, Conn.) Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax™ (Biogen, Inc., Cambridge, Mass.) Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. CapotenŽ and CapozideŽ from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. PrinivilŽ and PrinzideŽ from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name MevacorŽ from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, rapamycin and dexamethasone.
  • [0018]
    The dosage or concentration of the active agent required to produce a favorable therapeutic effect should be less than the level at which the active agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the active agent required to inhibit the desired cellular activity of the vascular region can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other therapeutic agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
  • Method of Applying the Composition
  • [0019]
    EFD spray device is an air-assisted external mixing atomizer. The composition is atomized into small droplets by air and uniformly applied to the stent surface. The atomization pressure can be maintained at a range of about 5 to 30 psi. The droplet size depends on such factors as viscosity of the solution, surface tension of the solvent, temperature of nozzle 18, and atomizing pressure.
  • [0020]
    During the application of the composition, stent 24 can be rotated about the stent's central longitudinal axis. Rotation of stent 24 can be from about 1 rpm to about 300 rpm, more narrowly about 50 rpm to about 150 rpm. By way of example, stent 24 can rotate at about 120 rpm. Stent 24 can also be a moved in a linear direction along the same axis. The stent can be moved at about 1 mm/sec. to about 12 mm/sec., for example about 6 mm/sec. for a minimum of at least two passes (i.e., back and forth passed the spray nozzle). The flow rate of the solution from the spray nozzle can be from about 0.01 mg/second to about 1.0 mg/second, for example about 0.1 mg/second.
  • [0021]
    For compositions having high viscosity and surface energy solvents (e.g., DMSO, DMAC, DMF, pyridine and dioxane), temperature controller 22 can be used to increase the temperature of applicator 14, more particularly nozzle 18 to a temperature above room temperature. Thus, the temperature of the composition leaving nozzle 18 would be greater than ambient temperature. For example, the temperature of the coating solution can be maintained between 35° C. to about 40° C. By increasing the temperature of the composition during the application of the composition to the stent, unexpected results have been achieved. Better coating uniformity and properties, such as lack of “cob webs” and “pool webs” have been observed by raising the temperature of the composition from ambient to between 35° C. to 40° C. By raising the temperature of the coating solution, the viscosity, surface energy, atomized droplet size of the solution can be reduced. Such effects have lead to improved wetting characteristics of the atomized solution on the metallic (e.g., stainless steel) surface of the stent. Another advantage gained by the apparatus of the present invention is the ability to increase the solid content in the solution, and thus deposit more coating per pass. Deposition of more solid content per pass leads to a reduction in the time of production of the stents.
  • [0022]
    In accordance with one embodiment, each repetition can be followed by removal of a significant amount of the solvent by application of a warm gas, such as air. The application of warm air between each repetition prevents coating defects and minimizes interaction between the active agent and the solvent. The temperature of the warm air can be about 30° C. to about 60° C., more narrolwy about 40° C. to about 50° C. The flow rate of the warm air can be from about 20 cubic feet/minute (CFM) (0.57 cubic meters/minute(CMM)) to about 80 CFM (2.27 CMM), more narrowly about 30 CFM (0.85 CMM) to about 40 CFM (1.13 CMM). The warn air can be applied for about 3 seconds to about 60 seconds, more narrowly about 10 seconds to about 20 seconds. Applications can be performed at a temperature of about 50° C., the flow rate of about 40 CFM, and for about 10 seconds. Any suitable number of sets of application of the composition followed by blowing of warm air can be performed to form a coating of a desired thickness or weight. Excessive application of the polymer can, however, cause coating defects.
  • [0023]
    In accordance with one embodiment, the stent can be least partially pre-expanded prior to the application of the composition. For example, the stent can be radially expanded about 20% to about 60%, more narrowly about 27% to about 55%—the measurement being taken from the stent's inner diameter at an unexpanded position to the inner diameter at the expanded position. The expansion of the stent, for increasing the interspace between the stent struts, during the application of the composition, can further prevent “cob web” or “pool web” formation between the stent struts.
  • EXAMPLES
  • [0024]
    The following Examples are provided by way of illustration and not limitation.
  • Example 1
  • [0025]
    A Eurotherm (model 2416) heating block was coupled to the nozzle of an EFD spray applicator (EFD 780S spray device with VALVEMATE 7040 control system). A 2 wt % composition of EVAL in DMAC solution was made. 0.67 wt % actinomycin D was added to the solution. The temperature of the nozzle was increased from room temperature to about 40° C. The temperature was allowed to stabilize prior to the spray process. Atomization pressure was set at 15 psi and the solution barrel pressure was set at about 2 to 5 psi. The composition was applied to the stent at a flow rate of 0.7 mg/sec of solution. The stent was rotated at about 150 rpm and moved back and forth at about 6 mm/sec for 30 cycles (1=cycle once back and forth passed the nozzle). The stent was dried by heated air at 55° C. for about 10 seconds. About 10 to 15 micrograms of coating was applied per cycle for a total of 400 micrograms. A 2 wt % of EVAL in DMAC solution was made for the topcoat solution. A rate-limiting barrier was then deposited on the drug matrix. The flow rate was set at 0.7 mg/sec of spray solution. A 400 microgram top-coat was deposited on the stent. A stent did not illustrate any significant formation of “cob webs.”
  • Example 2
  • [0026]
    A Eurotherm (model 2416) heating block was coupled to the nozzle of an EFD spray applicator (EFD 780S spray device with VALVEMATE 7040 control system). A 4 wt % stock solution of EVAL in DMAC was made, to be used for the primer layer and the top-coat layer. 1.34 wt % of actinomycin D was added to a portion of the composition for the drug solution. The composition was applied to the stent at a flow rate of 1.5 mg/sec of spray solution (20 to 25 micrograms semi-dry pick-up weight of the stent per spray cycle) for a total of 400 micrograms of drug coat and 400 micrograms of topcoat. During the application of the composition, the stent was rotated at about 150 rpm and moved back and forth at about 6 mm/sec for 20 cycles for each coating layer. The atomization air pressure was set at 15 psi. The heating temperature was set at 50° C. for drug coat and 60° C. for the topcoat. The stents were dried by application of heated air at 60° C. for 10 seconds. The stent did not illustrate any significant formation of “cob webs.”
  • [0027]
    While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from the embodiments this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of the embodiments this invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US6067480 *Apr 2, 1997May 23, 2000Stratasys, Inc.Method and apparatus for in-situ formation of three-dimensional solid objects by extrusion of polymeric materials
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7077910Apr 7, 2003Jul 18, 2006Surmodics, Inc.Linear rail coating apparatus and method
US7125577Oct 27, 2004Oct 24, 2006Surmodics, IncMethod and apparatus for coating of substrates
US7517547Jun 1, 2006Apr 14, 2009Sur Modics, Inc.Linear rail coating apparatus and method
US7648725May 19, 2006Jan 19, 2010Advanced Cardiovascular Systems, Inc.Clamp mandrel fixture and a method of using the same to minimize coating defects
US7648727Aug 26, 2004Jan 19, 2010Advanced Cardiovascular Systems, Inc.Methods for manufacturing a coated stent-balloon assembly
US7669548Mar 2, 2010Surmodics, Inc.Method and apparatus for coating of substrates
US7691401May 17, 2005Apr 6, 2010Advanced Cardiovascular Systems, Inc.Poly(butylmethacrylate) and rapamycin coated stent
US7699889May 2, 2008Apr 20, 2010Advanced Cardiovascular Systems, Inc.Poly(ester amide) block copolymers
US7713637Mar 3, 2006May 11, 2010Advanced Cardiovascular Systems, Inc.Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US7735449Jul 28, 2005Jun 15, 2010Advanced Cardiovascular Systems, Inc.Stent fixture having rounded support structures and method for use thereof
US7749263Jan 7, 2008Jul 6, 2010Abbott Cardiovascular Systems Inc.Poly(ester amide) filler blends for modulation of coating properties
US7758880Jul 20, 2010Advanced Cardiovascular Systems, Inc.Biocompatible polyacrylate compositions for medical applications
US7758881Jul 20, 2010Advanced Cardiovascular Systems, Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7766884May 25, 2007Aug 3, 2010Advanced Cardiovascular Systems, Inc.Polymers of fluorinated monomers and hydrophilic monomers
US7772359Sep 9, 2008Aug 10, 2010Advanced Cardiovascular Systems, Inc.Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7775178May 26, 2006Aug 17, 2010Advanced Cardiovascular Systems, Inc.Stent coating apparatus and method
US7776382Mar 24, 2006Aug 17, 2010Surmodics, IncAdvanced coating apparatus and method
US7776926Dec 11, 2002Aug 17, 2010Advanced Cardiovascular Systems, Inc.Biocompatible coating for implantable medical devices
US7785512May 25, 2004Aug 31, 2010Advanced Cardiovascular Systems, Inc.Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7785647Aug 31, 2010Advanced Cardiovascular Systems, Inc.Methods of providing antioxidants to a drug containing product
US7786249Sep 9, 2008Aug 31, 2010Advanced Cardiovascular Systems, Inc.Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7794743Sep 14, 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of making the same
US7795467Sep 14, 2010Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US7803394Nov 17, 2006Sep 28, 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide hydrogel coatings for cardiovascular therapy
US7803406Aug 26, 2005Sep 28, 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of coating implantable medical devices
US7807210Apr 5, 2004Oct 5, 2010Advanced Cardiovascular Systems, Inc.Hemocompatible polymers on hydrophobic porous polymers
US7807211May 27, 2004Oct 5, 2010Advanced Cardiovascular Systems, Inc.Thermal treatment of an implantable medical device
US7820732Oct 26, 2010Advanced Cardiovascular Systems, Inc.Methods for modulating thermal and mechanical properties of coatings on implantable devices
US7823533Nov 2, 2010Advanced Cardiovascular Systems, Inc.Stent fixture and method for reducing coating defects
US7867547Dec 19, 2005Jan 11, 2011Advanced Cardiovascular Systems, Inc.Selectively coating luminal surfaces of stents
US7875286Jan 25, 2011Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of coating implantable medical devices
US7892592Feb 22, 2011Advanced Cardiovascular Systems, Inc.Coating abluminal surfaces of stents and other implantable medical devices
US7901703Mar 23, 2007Mar 8, 2011Advanced Cardiovascular Systems, Inc.Polycationic peptides for cardiovascular therapy
US7958840Jun 14, 2011Surmodics, Inc.Method and apparatus for coating of substrates
US7976891Jul 12, 2011Advanced Cardiovascular Systems, Inc.Abluminal stent coating apparatus and method of using focused acoustic energy
US7985440Sep 7, 2005Jul 26, 2011Advanced Cardiovascular Systems, Inc.Method of using a mandrel to coat a stent
US7985441May 4, 2006Jul 26, 2011Yiwen TangPurification of polymers for coating applications
US8003156May 4, 2006Aug 23, 2011Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8007775Aug 30, 2011Advanced Cardiovascular Systems, Inc.Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US8017140Sep 13, 2011Advanced Cardiovascular System, Inc.Drug-delivery stent formulations for restenosis and vulnerable plaque
US8017237Sep 13, 2011Abbott Cardiovascular Systems, Inc.Nanoshells on polymers
US8021676Jul 8, 2005Sep 20, 2011Advanced Cardiovascular Systems, Inc.Functionalized chemically inert polymers for coatings
US8029816Oct 4, 2011Abbott Cardiovascular Systems Inc.Medical device coated with a coating containing elastin pentapeptide VGVPG
US8048441Nov 1, 2011Abbott Cardiovascular Systems, Inc.Nanobead releasing medical devices
US8048448Nov 1, 2011Abbott Cardiovascular Systems Inc.Nanoshells for drug delivery
US8052912Nov 8, 2011Advanced Cardiovascular Systems, Inc.Temperature controlled crimping
US8062350Nov 22, 2011Abbott Cardiovascular Systems Inc.RGD peptide attached to bioabsorbable stents
US8067023Nov 29, 2011Advanced Cardiovascular Systems, Inc.Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
US8067025Mar 20, 2007Nov 29, 2011Advanced Cardiovascular Systems, Inc.Nitric oxide generating medical devices
US8069814Dec 6, 2011Advanced Cardiovascular Systems, Inc.Stent support devices
US8109904Feb 7, 2012Abbott Cardiovascular Systems Inc.Drug delivery medical devices
US8110211Sep 22, 2004Feb 7, 2012Advanced Cardiovascular Systems, Inc.Medicated coatings for implantable medical devices including polyacrylates
US8114150Jun 14, 2006Feb 14, 2012Advanced Cardiovascular Systems, Inc.RGD peptide attached to bioabsorbable stents
US8118863Feb 21, 2008Feb 21, 2012Abbott Cardiovascular Systems Inc.RGD peptide attached to bioabsorbable stents
US8147769May 16, 2007Apr 3, 2012Abbott Cardiovascular Systems Inc.Stent and delivery system with reduced chemical degradation
US8173199May 8, 2012Advanced Cardiovascular Systems, Inc.40-O-(2-hydroxy)ethyl-rapamycin coated stent
US8192752Jun 5, 2012Advanced Cardiovascular Systems, Inc.Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US8192785Jan 3, 2007Jun 5, 2012Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US8197879Jun 12, 2012Advanced Cardiovascular Systems, Inc.Method for selectively coating surfaces of a stent
US8293367Jul 15, 2011Oct 23, 2012Advanced Cardiovascular Systems, Inc.Nanoshells on polymers
US8293890Apr 30, 2004Oct 23, 2012Advanced Cardiovascular Systems, Inc.Hyaluronic acid based copolymers
US8303651Nov 6, 2012Advanced Cardiovascular Systems, Inc.Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US8304012 *Nov 6, 2012Advanced Cardiovascular Systems, Inc.Method for drying a stent
US8357391Jan 22, 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US8435550May 7, 2013Abbot Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8465789Jul 18, 2011Jun 18, 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8506617Jun 21, 2002Aug 13, 2013Advanced Cardiovascular Systems, Inc.Micronized peptide coated stent
US8529983May 21, 2010Sep 10, 2013Envision Scientific Pvt. Ltd.Method and system for coating insertable medical devices
US8568764May 31, 2006Oct 29, 2013Advanced Cardiovascular Systems, Inc.Methods of forming coating layers for medical devices utilizing flash vaporization
US8586069Dec 29, 2005Nov 19, 2013Abbott Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US8586075Nov 27, 2012Nov 19, 2013Abbott Cardiovascular Systems Inc.Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages
US8592036Sep 20, 2012Nov 26, 2013Abbott Cardiovascular Systems Inc.Nanoshells on polymers
US8596215Jul 18, 2011Dec 3, 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8597673Dec 13, 2006Dec 3, 2013Advanced Cardiovascular Systems, Inc.Coating of fast absorption or dissolution
US8603530Jun 14, 2006Dec 10, 2013Abbott Cardiovascular Systems Inc.Nanoshell therapy
US8603634Mar 23, 2009Dec 10, 2013Abbott Cardiovascular Systems Inc.End-capped poly(ester amide) copolymers
US8609123Nov 29, 2004Dec 17, 2013Advanced Cardiovascular Systems, Inc.Derivatized poly(ester amide) as a biobeneficial coating
US8616152 *Aug 6, 2012Dec 31, 2013Abbott Cardiovascular Systems Inc.Stent coating apparatus
US8637110Jul 18, 2011Jan 28, 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8647655Jun 18, 2010Feb 11, 2014Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US8673334Sep 19, 2007Mar 18, 2014Abbott Cardiovascular Systems Inc.Stent coatings comprising hydrophilic additives
US8685431Mar 16, 2004Apr 1, 2014Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8703167Jun 5, 2006Apr 22, 2014Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US8703169Aug 8, 2007Apr 22, 2014Abbott Cardiovascular Systems Inc.Implantable device having a coating comprising carrageenan and a biostable polymer
US8741378Dec 23, 2004Jun 3, 2014Advanced Cardiovascular Systems, Inc.Methods of coating an implantable device
US8741379Jul 18, 2011Jun 3, 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8758801Nov 27, 2012Jun 24, 2014Abbott Cardiocascular Systems Inc.Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages
US8778014Mar 31, 2004Jul 15, 2014Advanced Cardiovascular Systems, Inc.Coatings for preventing balloon damage to polymer coated stents
US8778375Apr 29, 2005Jul 15, 2014Advanced Cardiovascular Systems, Inc.Amorphous poly(D,L-lactide) coating
US8778376Jun 9, 2006Jul 15, 2014Advanced Cardiovascular Systems, Inc.Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US8808342Apr 23, 2013Aug 19, 2014Abbott Cardiovascular Systems Inc.Nanoshell therapy
US8871236Jun 6, 2013Oct 28, 2014Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US8871883Jul 27, 2010Oct 28, 2014Abbott Cardiovascular Systems Inc.Biocompatible coating for implantable medical devices
US8927050Nov 5, 2012Jan 6, 2015Abbott Cardiovascular Systems Inc.Method and apparatus for coating a stent
US8961588Sep 26, 2006Feb 24, 2015Advanced Cardiovascular Systems, Inc.Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US8986726Jun 6, 2013Mar 24, 2015Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US9028859Jul 7, 2006May 12, 2015Advanced Cardiovascular Systems, Inc.Phase-separated block copolymer coatings for implantable medical devices
US9056155May 29, 2007Jun 16, 2015Abbott Cardiovascular Systems Inc.Coatings having an elastic primer layer
US9067000Nov 18, 2013Jun 30, 2015Abbott Cardiovascular Systems Inc.End-capped poly(ester amide) copolymers
US9084671Jul 15, 2013Jul 21, 2015Advanced Cardiovascular Systems, Inc.Methods of forming a micronized peptide coated stent
US9101697Apr 11, 2014Aug 11, 2015Abbott Cardiovascular Systems Inc.Hyaluronic acid based copolymers
US9114198Nov 19, 2003Aug 25, 2015Advanced Cardiovascular Systems, Inc.Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US9175162Sep 19, 2007Nov 3, 2015Advanced Cardiovascular Systems, Inc.Methods for forming stent coatings comprising hydrophilic additives
US9283350Oct 25, 2013Mar 15, 2016Surmodics, Inc.Coating apparatus and methods
US9308355May 31, 2013Apr 12, 2016Surmodies, Inc.Apparatus and methods for coating medical devices
US20020198344 *Apr 5, 2002Dec 26, 2002Wolfgang VoigtStabilized medium and high voltage cable insulation composition
US20040182312 *Mar 30, 2004Sep 23, 2004Pacetti Stephen DApparatus and method for coating implantable devices
US20040194704 *Apr 7, 2003Oct 7, 2004Surmodics, Inc.Linear rail coating apparatus and method
US20050100609 *Dec 16, 2004May 12, 2005Claude Charles D.Phase-separated polymer coatings
US20050106204 *Nov 19, 2003May 19, 2005Hossainy Syed F.Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US20050112171 *Nov 21, 2003May 26, 2005Yiwen TangCoatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US20050131201 *Dec 16, 2003Jun 16, 2005Pacetti Stephen D.Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US20050137381 *Dec 19, 2003Jun 23, 2005Pacetti Stephen D.Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20050158449 *Oct 27, 2004Jul 21, 2005Chappa Ralph A.Method and apparatus for coating of substrates
US20050186248 *Feb 22, 2005Aug 25, 2005Hossainy Syed F.Stent coating
US20050191332 *Feb 7, 2005Sep 1, 2005Hossainy Syed F.Method of forming rate limiting barriers for implantable devices
US20050208091 *Mar 16, 2004Sep 22, 2005Pacetti Stephen DBiologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US20050233062 *May 27, 2004Oct 20, 2005Hossainy Syed FThermal treatment of an implantable medical device
US20050238686 *Mar 25, 2005Oct 27, 2005Advanced Cardiovascular Systems, Inc.Coating for implantable devices and a method of forming the same
US20050244363 *Apr 30, 2004Nov 3, 2005Hossainy Syed F AHyaluronic acid based copolymers
US20050266038 *May 27, 2004Dec 1, 2005Thierry GlauserAntifouling heparin coatings
US20050287184 *Jun 29, 2004Dec 29, 2005Hossainy Syed F ADrug-delivery stent formulations for restenosis and vulnerable plaque
US20060002968 *Jun 30, 2004Jan 5, 2006Gordon StewartAnti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US20060002974 *Aug 26, 2005Jan 5, 2006Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of coating implantable medical devices
US20060014720 *Sep 15, 2005Jan 19, 2006Advanced Cardiovascular Systems, Inc.Heparin prodrugs and drug delivery stents formed therefrom
US20060034888 *Jul 30, 2004Feb 16, 2006Advanced Cardiovascular Systems, Inc.Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US20060035012 *Sep 7, 2005Feb 16, 2006Advanced Cardiovascular Systems, Inc.Method of using a mandrel to coat a stent
US20060047095 *Aug 31, 2004Mar 2, 2006Pacetti Stephen DPolymers of fluorinated monomers and hydrophilic monomers
US20060062821 *Sep 2, 2005Mar 23, 2006Simhambhatla Murthy VPolycationic peptide coatings and methods of making the same
US20060062824 *Sep 22, 2004Mar 23, 2006Advanced Cardiovascular Systems, Inc.Medicated coatings for implantable medical devices including polyacrylates
US20060065193 *Sep 7, 2005Mar 30, 2006Advanced Cardiovascular Systems, Inc.Device for supporting a stent during coating of the stent
US20060074191 *Oct 6, 2004Apr 6, 2006Desnoyer Jessica RBlends of poly(ester amide) polymers
US20060088653 *Oct 27, 2004Apr 27, 2006Chappa Ralph AMethod and apparatus for coating of substrates
US20060089485 *Oct 27, 2004Apr 27, 2006Desnoyer Jessica REnd-capped poly(ester amide) copolymers
US20060093842 *Oct 29, 2004May 4, 2006Desnoyer Jessica RPoly(ester amide) filler blends for modulation of coating properties
US20060095122 *Oct 29, 2004May 4, 2006Advanced Cardiovascular Systems, Inc.Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US20060115449 *Nov 30, 2004Jun 1, 2006Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US20060115513 *Nov 29, 2004Jun 1, 2006Hossainy Syed F ADerivatized poly(ester amide) as a biobeneficial coating
US20060134165 *Dec 22, 2004Jun 22, 2006Pacetti Stephen DPolymers of fluorinated monomers and hydrocarbon monomers
US20060147412 *Dec 30, 2004Jul 6, 2006Hossainy Syed FPolymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US20060160985 *Jan 14, 2005Jul 20, 2006Pacetti Stephen DPoly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
US20060165872 *Mar 24, 2006Jul 27, 2006Chappa Ralph AAdvanced coating apparatus and method
US20060207501 *May 19, 2006Sep 21, 2006Advanced Cardiovascular Systems, Inc.Clamp mandrel fixture and a method of using the same to minimize coating defects
US20060210701 *Jun 1, 2006Sep 21, 2006Surmodics, Inc.Linear Rail Coating Apparatus and Method
US20060210702 *May 19, 2006Sep 21, 2006Advanced Cardiovascular Systems, Inc.Clamp mandrel fixture and a method of using the same to minimize coating defects
US20070003688 *Jun 30, 2005Jan 4, 2007Advanced Cardiovascular Systems, Inc.Stent fixture and method for reducing coating defects
US20070016284 *Sep 22, 2006Jan 18, 2007Advanced Cardiovascular Systems, Inc.Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US20070020380 *Jul 25, 2005Jan 25, 2007Ni DingMethods of providing antioxidants to a drug containing product
US20070020381 *Sep 26, 2006Jan 25, 2007Advanced Cardiovascular Systems, Inc.40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20070020382 *Sep 26, 2006Jan 25, 2007Advanced Cardiovascular Systems, Inc.40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20070101933 *Oct 6, 2006May 10, 2007Surmodics, Inc.Method and Apparatus for Coating of Substrates
US20070110891 *Jan 3, 2007May 17, 2007Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US20070128246 *Dec 6, 2005Jun 7, 2007Hossainy Syed F ASolventless method for forming a coating
US20070128342 *Dec 2, 2005Jun 7, 2007Stenzel Eric BMethod and system for coating a medical device
US20070135909 *Dec 8, 2005Jun 14, 2007Desnoyer Jessica RAdhesion polymers to improve stent retention
US20070167602 *Mar 21, 2007Jul 19, 2007Advanced Cardiovascular SystemsBiologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US20070196424 *Mar 20, 2007Aug 23, 2007Advanced Cardiovascular Systems, Inc.Nitric oxide generating medical devices
US20070196428 *Feb 17, 2006Aug 23, 2007Thierry GlauserNitric oxide generating medical devices
US20070198080 *Sep 27, 2006Aug 23, 2007Ni DingCoatings including an antioxidant
US20070198081 *Dec 5, 2006Aug 23, 2007Daniel CastroPoly(butylmethacrylate) and rapamycin coated stent
US20070202323 *Feb 28, 2006Aug 30, 2007Kleiner Lothar WCoating construct containing poly (vinyl alcohol)
US20070207181 *Mar 3, 2006Sep 6, 2007Kleiner Lothar WCoating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US20070231363 *Mar 29, 2006Oct 4, 2007Yung-Ming ChenCoatings formed from stimulus-sensitive material
US20070249801 *Mar 22, 2007Oct 25, 2007Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US20070259101 *Jun 5, 2006Nov 8, 2007Kleiner Lothar WMicroporous coating on medical devices
US20070259102 *May 4, 2006Nov 8, 2007Mcniven AndrewMethods and devices for coating stents
US20070286882 *Jun 9, 2006Dec 13, 2007Yiwen TangSolvent systems for coating medical devices
US20080021008 *Sep 19, 2007Jan 24, 2008Advanced Cardiovascular Systems, Inc.Stent coatings comprising hydrophilic additives
US20080038310 *May 10, 2007Feb 14, 2008Hossainy Syed F ACoating comprising an elastin-based copolymer
US20080118543 *Sep 19, 2007May 22, 2008Advanced Cardiovascular Systems, Inc.Stent Coatings comprising hydrophilic additives
US20080125857 *Jan 28, 2008May 29, 2008Advanced Cardiovascular Systems, Inc.Hemocompatible polymers on hydrophobic porous polymers
US20080132592 *Jan 28, 2008Jun 5, 2008Advanced Cardiovascular Systems Inc.Hemocompatible polymers on hydrophobic porous polymers
US20080145393 *Dec 13, 2006Jun 19, 2008Trollsas Mikael OCoating of fast absorption or dissolution
US20080167712 *Jan 7, 2008Jul 10, 2008Advanced Cardiovascular Systems, Inc.Poly(ester amide) filler blends for modulation of coating properties
US20080177008 *Mar 26, 2008Jul 24, 2008Advanced Cardiovascular Systems Inc.Blends Of Poly(Ester Amide) Polymers
US20080206306 *May 2, 2008Aug 28, 2008Syed Faiyaz Ahmed HossainyPoly(ester amide) block copolymers
US20080226812 *May 26, 2006Sep 18, 2008Yung Ming ChenStent coating apparatus and method
US20080262606 *Jun 9, 2008Oct 23, 2008Ni DingPolymers containing siloxane monomers
US20090012243 *Sep 9, 2008Jan 8, 2009Pacetti Stephen DBiobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20090012259 *Sep 9, 2008Jan 8, 2009Pacetti Stephen DBiobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20090012606 *Sep 9, 2008Jan 8, 2009Pacetti Stephen DBiobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20090041845 *Aug 8, 2007Feb 12, 2009Lothar Walter KleinerImplantable medical devices having thin absorbable coatings
US20090232865 *Mar 23, 2009Sep 17, 2009Abbott Cardiovascular Systems Inc.End-Capped Poly(Ester Amide) Copolymers
US20100215436 *Jul 17, 2008Aug 26, 2010William Nevil Heaton JohnsonFlood barrier or the like
US20100292426 *Nov 18, 2010Hossainy Syed F ABiocompatible coating for implantable medical devices
US20120291703 *Nov 22, 2012Advanced Cardiovascular Systems, Inc.Stent coating apparatus
USRE40722Jun 26, 2007Jun 9, 2009Surmodics, Inc.Method and apparatus for coating of substrates
USRE45744Nov 7, 2013Oct 13, 2015Abbott Cardiovascular Systems Inc.Temperature controlled crimping
EP1568394A1 *Feb 26, 2004Aug 31, 2005Muijs van de Moer, Wouter MatthijsCoated electrode
WO2004091682A1 *Apr 6, 2004Oct 28, 2004Surmodics, Inc.Linear rail coating apparatus and method
WO2007067293A2 *Nov 6, 2006Jun 14, 2007Boston Scientific Scimed, Inc.Method and system for coating a medical device
WO2007067293A3 *Nov 6, 2006May 29, 2008Boston Scient Scimed IncMethod and system for coating a medical device
WO2011086569A1 *May 21, 2010Jul 21, 2011Concept Medical Research Private LimitedMethod and system for coating insertable medical devices
Classifications
U.S. Classification427/2.1, 118/667, 118/300
International ClassificationA61L31/16, A61L31/10, B05B12/10
Cooperative ClassificationA61L2300/606, A61L31/16, A61L31/10, B05B12/10
European ClassificationA61L31/10, B05B12/10, A61L31/16
Legal Events
DateCodeEventDescription
Sep 27, 2001ASAssignment
Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, YUNG-MING;BOBSON, CHARLES R.;LOPRETE, JOHN F.;REEL/FRAME:012220/0401
Effective date: 20010924
Oct 4, 2001ASAssignment
Owner name: PIONEER CORPORATION, JAPAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIURA, SATOSHI;TACHIBANA, AKIHIRO;YAMAKAWA, YUZO;REEL/FRAME:012229/0916
Effective date: 20010918